We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-30.82%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.7B
AUM Growth
-$1.14B
Cap. Flow
+$156M
Cap. Flow %
5.8%
Top 10 Hldgs %
59.73%
Holding
123
New
18
Increased
25
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$86.4M
2
BABA icon
Alibaba
BABA
+$51.3M
3
NIO icon
NIO
NIO
+$28.5M
4
ALLO icon
Allogene Therapeutics
ALLO
+$10.6M
5
ARRY
Array Biopharma Inc
ARRY
+$9.1M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$31.2M
2
ANAB icon
AnaptysBio
ANAB
+$11.2M
3
FOLD
Amicus Therapeutics
FOLD
+$11M
4
ZGNX
Zogenix, Inc.
ZGNX
+$8.19M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.69M

Sector Composition

Rank Sector Weight
1 Healthcare 49.34%
2 Miscellaneous 25.7%
3 Consumer Discretionary 24.57%
4 Real Estate 0.28%
5 Communication Services 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRO icon
76
Spero Therapeutics
SPRO
$65.8M
$3.69M 0.14%
600,000
– –
CLVS
77
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.59M 0.13%
+200,000
New +$4.09M
LRMR icon
78
Larimar Therapeutics
LRMR
$393M
$3.46M 0.13%
58,333
-8,334
-13% -$823K
TWST icon
79
Twist Bioscience
TWST
$8.93B
$3.46M 0.13%
+150,000
New +$3.32M
ACET icon
80
Adicet Bio
ACET
$90.8M
$3.45M 0.13%
3,571
-893
-20% -$1.18M
RCUS icon
81
Arcus Biosciences
RCUS
$3.06B
$3.23M 0.12%
300,000
– –
Z icon
82
Zillow
Z
$7.46B
$3.16M 0.12%
+100,000
New +$3.55M
GRTS
83
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$3.09M 0.11%
200,000
– –
TCDA
84
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.95M 0.11%
125,000
+25,000
+25% +$718K
MRUS
85
DELISTED
Merus
MRUS
$2.89M 0.11%
+206,125
New +$2.98M
YI
86
111 Inc
YI
$31.6M
$2.76M 0.1%
45,000
– –
WHWK
87
Whitehawk Therapeutics
WHWK
$234M
$2.65M 0.1%
103,893
– –
KDNY
88
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.64M 0.1%
200,000
+90,000
+82% +$1.8M
AKBA icon
89
Akebia Therapeutics
AKBA
$267M
$2.63M 0.1%
475,000
– –
CMRX
90
DELISTED
Chimerix, Inc.
CMRX
$2.57M 0.1%
1,000,000
– –
CTMX icon
91
CytomX Therapeutics
CTMX
$697M
$2.27M 0.08%
+150,000
New +$2.23M
QTTB icon
92
Q32 Bio
QTTB
$330M
$2.24M 0.08%
5,556
– –
MNTA
93
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.21M 0.08%
+200,000
New +$2.78M
ALDR
94
DELISTED
Alder Biopharmaceuticals
ALDR
$2.05M 0.08%
+200,000
New +$2.56M
TECX
95
Tectonic Therapeutic
TECX
$568M
$1.67M 0.06%
8,333
– –
TGTX icon
96
TG Therapeutics
TGTX
$8.25B
$1.64M 0.06%
400,000
– –
RNAC icon
97
Cartesian Therapeutics
RNAC
$248M
$1.6M 0.06%
20,000
+1,282
+7% +$293K
VRDN icon
98
Viridian Therapeutics
VRDN
$2.52B
$1.51M 0.06%
33,333
– –
MRNS
99
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.44M 0.05%
125,000
– –
IRWD icon
100
Ironwood Pharmaceuticals
IRWD
$689M
$1.15M 0.04%
131,975
– –
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2018 Portfolio in Review

As of Q4 2018, Artal Group held 123 positions worth $2.7B, down 30% from $3.84B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group deployed $156M of net new capital in Q4 2018, opening 18 new positions and adding to 25 existing holdings. Its largest new stake was Moderna: 5,256,298 shares worth $80.3M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 46% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $11.2M trimmed.

  • Artal Group's largest Q4 2018 buy was Moderna: 5,256,298 shares worth $80.3M.
  • Artal Group added most to Alibaba in Q4 2018, an estimated $51.3M increase.
  • Artal Group's biggest Q4 2018 reduction was AnaptysBio, cutting an estimated $11.2M.
  • Artal Group fully exited TESARO, Inc. in Q4 2018, selling an estimated $31.2M.
  • Artal Group's ten largest holdings make up 60% of its $2.7B portfolio in Q4 2018.
  • Artal Group opened 18 new positions and closed 19 in Q4 2018.
  • Artal Group's portfolio value fell 30% quarter-over-quarter to $2.7B.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.